DermNet provides Google Translate, a free machine translation service. Note that this may not provide an exact translation in all languages
Oral treatment is often prescribed for acne. The choice depends on:
Systemic antibacterials for the treatment of moderate-to-severe acne include tetracycline, doxycycline, minocycline, erythromycin and trimethoprim + sulphamethoxazole. They reduce the number of pathogenic organisms and they have anti-inflammatory actions, for example reducing Cutibacterium acnes-induced neutrophil chemotaxis and reactive-oxygen species.
Poor clinical response can be due to:
The same antibacterial should be prescribed for at least 3 months and usually for an average of 6 months. To prevent the development of resistance, they should be combined with a topical retinoid or benzoyl peroxide rather than a topical antibiotic. Systemic isotretinoin should be considered if one or two antibacterials have been tried without success.
Other chronic skin diseases routinely treated with antibiotics include:
Antibiotics are used empirically in these conditions. There are very few published randomised blinded trials to support their use, but benefit is generally self-evident in practice. Mostly the mechanism of action is unknown; probably an anti-inflammatory effect in most conditions but antimicrobial action may be important in others.
Tetracyclines are particularly useful as they are well tolerated and generally safe when used long term. In children under 8 and pregnant females it can be replaced by erythromycin, but this is probably less effective and has important interactions with other drugs. Because of a higher risk of serious adverse events, cotrimoxazole is rarely indicated.
Hypersensitivity to tetracyclines may result in:
Other adverse effects include:
Hormonal treatment is an alternative regimen in female acne, especially in the presence of polycystic ovarian syndrome or when oral contraception is desired.
Cmbined oral contraceptives containing ethinyl oestrodiol and minimally androgenic progesterones such as desogestrel (Marvelon™, Mercilon™), gestodene (Femodene™, Minulet™) or norgestimate should be tried initially, for a 3 to 6-month course as a minimum. Progestogen-only pills are generally ineffective. Injected medroxyprogesterone (Depo Provera™) tends to aggravate acne.
Specific anti-androgenic contraceptive pills have a combination of ethinyl estradiol and progestins such as cyproterone acetate (Diane 35™, Estelle 35™), drospirenone (Yasmin™, Yaz™) or dienogest. The result is reduced seborrhoea in 80% of users, improvement in acne (up to 70%), in hirsutism (up to 40%) and androgen-related alopecia (up to 80%). They are generally well tolerated (especially those contining drospirenone or dienogest), the main adverse effects of being nonspecific or as expected (headache, breast tenderness and nausea). They have no clinically relevant effects on metabolic or liver functions or on bodyweight. However, those containing cyproterone have been reported to be twice as likely to cause venous thromboembolic disease as second generation pills.
Larger doses of cyproterone are sometimes used to treat hirsutism and polycystic ovarian syndrome but are rarely necessary for acne. Each cycle, 50-200mg is taken for 10 days and is usually combined with an oral contraceptive. Main adverse effects are menstrual irregularities, weight increase and depression.
Spironolactone also has antiandrogenic effects. It is used to treat female acne and hirsutism at a dose of 50 mg twice weekly to 200mg once daily. Main adverse effects are breast pain and menstrual irregularities (combine with oral contraceptive agent).
Isotretinoin is an extremely effective treatment for acne and appears to work by reducing sebum production. The indications are:
It is also used for antibiotic-resistant rosacea, folliculitis and rarely other inflammatory skin diseases. In New Zealand Pharmaceutical Schedule subsidy is restricted and requires Special Authority application.
It has numerous side effects primarily mucocutaneous dryness.
A course of isotretinoin 0.5-1 mg/kg/day ranges from 4 to 12 months (usually 5 to 6 months) and may be repeated if necessary.
Review the evidence that anti-acne medication improves or aggravates depression in adolescents with acne.
Information for patients
See the DermNet NZ bookstore
© 2019 DermNet New Zealand Trust.
DermNet NZ does not provide an online consultation service. If you have any concerns with your skin or its treatment, see a dermatologist for advice.